文献速递妇科

舒尼替尼治疗持续性或复发性透明细胞卵巢癌的II期评估:NRG肿瘤学/妇科肿瘤学组研究(GOG-254)

A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
PubMed 文献 · Gynecol Oncol · 2018-06-18

本研究为II期临床试验,评估舒尼替尼在持续性或复发性透明细胞卵巢癌患者中的疗效和耐受性。35例患者入组,30例可评估,舒尼替尼50 mg/日,用药4周停2周,6周为一周期。6个月无进展生存率为16.7%,客观缓解率为6.7%,中位无进展生存期2.7个月,中位总生存期12.8个月。结论为舒尼替尼在二线和三线治疗中活性有限。

要点

  • 舒尼替尼在复发性透明细胞卵巢癌中6个月无进展生存率为16.7%,客观缓解率为6.7%。
  • 中位无进展生存期2.7个月,中位总生存期12.8个月。
  • 常见3级不良事件包括乏力、高血压、中性粒细胞减少、贫血、腹痛和白细胞减少。

核心结论

  • 舒尼替尼在持续性或复发性透明细胞卵巢癌的二线和三线治疗中显示最小活性。

研究设计与样本

  • II期临床试验,入组35例,30例接受治疗并可评估,中位年龄51岁(范围27-73岁)。
  • 患者既往接受过一或两种方案且有可测量病灶,肿瘤至少50%为透明细胞组织形态学,且WT-1抗原和雌激素受体免疫组化表达阴性。
  • 舒尼替尼50 mg/日,用药4周停2周,6周为一周期,直至疾病进展或不可耐受毒性。
  • 主要终点为6个月无进展生存率和临床缓解率,设计旨在确定药物缓解率是否至少20%或6个月无进展生存率是否至少25%。

主要发现

  • 5例(16.7%)患者无进展生存期≥6个月(90% CI:6.8%-31.9%)。
  • 2例(6.7%)患者达到部分或完全缓解(90% CI:1.2%-19.5%)。
  • 中位无进展生存期2.7个月,中位总生存期12.8个月。
  • 最常见的3级不良事件为乏力(4例)、高血压(4例)、中性粒细胞减少(4例)、贫血(3例)、腹痛(3例)和白细胞减少(3例)。
  • 4-5级不良事件包括血小板减少(5例)、贫血(2例)、急性肾损伤(1例)、卒中(1例)和过敏反应(1例)。

关键数值与推荐

  • 6个月无进展生存率为16.7%(90% CI:6.8%-31.9%)。
  • 客观缓解率为6.7%(90% CI:1.2%-19.5%)。
  • 中位无进展生存期2.7个月,中位总生存期12.8个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the efficacy and tolerability of sunitinib in recurrent or persistent clear cell ovarian cancer patients. METHODS: All patients had one or two prior regimens with measurable disease. Tumors were at least 50% clear cell histomorphology and negative for WT-1 antigen and estrogen receptor expression by immunohistochemistry. Sunitinib 50 mg per day for 4 weeks was administered in repeated 6-week cycles until disease progression or prohibitive toxicity. Primary end points were progression-free survival (PFS) at 6 months and clinical response. The study was designed to determine if the drug had a response rate of at least 20% or 6-month PFS of at least 25%. RESULTS: Of 35 patients enrolled, 30 were treated and eligible (median age: 51, range: 27-73). Twenty-five (83%) were White, 4 (13%) Asian, and 1 (3%) unknown. The majority 28 (83%) patients, underwent ≤3 but 2 (7%) had 16 courses of study therapy. Five (16.7%) patients had PFS ≥6 months (90% CI: 6.8%-31.9%). Two (6.7%) patients had a partial or complete response (90% CI: 1.2%-19.5%). The median PFS was 2.7 months. The median overall survival was 12.8 months. The most common grade 3 adverse events were fatigue (4), hypertension (4), neutropenia (4), anemia (3), abdominal pain (3), and leukopenia (3). Grade 4-5 adverse events included: thrombocytopenia (5), anemia (2), acute kidney Injury (1), stroke (1), and allergic reaction (1). CONCLUSION: Sunitinib demonstrated minimal activity in the second- and third-line treatment of persistent or recurrent clear cell ovarian carcinoma. ClinicalTrials.gov number, NCT00979992.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Chan JK, Brady W, Monk BJ, et al. A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). Gynecol Oncol. 2018. PMID: 29921512. doi:10.1016/j.ygyno.2018.05.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。